S. pneumoniae invasive infection remains a significant cause of death after allogeneic stem cell transplant (Engelhard et al. BJH 2002) . The protective effect of the polysaccharide 23-valent vaccine is not satisfactory, due to the poor antibody response of the SCT population. Conjugate vaccine are more immunogenic than PS vaccines in the normal population. The goal of this study is to compare the immune response to early (d100) versus late (9 months) post-transplant immunization with three doses of the heptavalent pneumococcal conjugate vaccine (Prevenar®, Wyeth-Lederlé) given at one month interval, in allogeneic stemcell recipients. This is a prospective, randomised, open study conducted in 15 EBMT centers of 7 countries, according to the Guidelines for EBMT trials, and supported by Wyeth-Lederlé. Randomisation is done between day 85-day 109, to receive 3 injections of Prevenar® at one month interval, beginning either on d100 ± 10 (Early Group), or at 9 months ± 10 days (Late Group), followed by one dose of 23-valent polysaccharide vaccine administered at 12 and 18 months post-transplant, respectively. The primary endpoint is the percentage of responders, defined as an antibody titer >/= 15 µg/ml, to all the 7 serotypes present in the conjugated vaccine, one month after the third dose of Prevenar®. Patients transplanted with a nonmyeloablative regimen are not included, as those with S. pneumoniae infection between transplant and d100. S. pneumoniae invasive infections are collected until 24 months post-transplant. Up to November 13, 2002, 36 patients were included. A first estimation of the response rate will be done when 70 patients will have received 2 doses of Prevenar.
Oral Session: Acute leukemia and Secondary AML / MDS
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Outcomes of HLA identical siblings are comparable to unrelated bone marrow transplants in adults with acute lymphoblastic leukemia V. Rocha, M. Labopin, T. Ruutu, N. Basara, J.P. Jouet, E. Gluckman, O. Rigden, W. Arcese, E. Polge, N.C. Gorin, J. Finke, D. Hoelzer, F 
. Frassoni on behalf of the Acute Leukemia Working Party
In order to compare HLA i dentical siblings bone marrow transplants (genoid-BMT) with HLA matched unrelated BMT (MUD) we analysed patients with ALL older than 16 years receiving a non-manipulated BMT from 1994 to 2001 and for whom cytogenetic abnormality was known. Six hundred twenty three patients were studied, 428 received a genoid-BMT and 195 a MUD (HLA compatibility defined as HLA-A, -B by serology and DRB1 allelic typing). Univariable and multivariable analyses, using relapse and death as competing event, were performed to study risk factors for transplant-related mortality (TRM) and relapse incidence (RI). Event-free survival (EFS) and other times to event were estimated using Cox models after adjustment for patient-,disease-and transplant-related factors that could potentially affect outcomes. Results: main statistical differences between the two groups were: MUD were transplanted more frequently in >=CR3 or relapse compared to genoid-BMT (38% vs 18%, p<0.01) and with Philadelphia positive (Phi+) chromosome (35% vs 24%, p=0.004) respectively. Unrelated donors were older than HLA identical sibs (p<0.0001). A female donor to male recipient was less frequently used in MUD (18%) compared to genoid-BMT (24%) (p=0.09) and TBI containing regimen more frequently administered to MUD (p=0.06). Other characteristics such as WBC, patients age and gender, number of nucleated cell dose, GvHD prophylaxis were not statistically different between the two groups. Graft failure was observed in 4% of genoid-BMT compared to 11% in MUD (p=0.001). Acute GvHD (>=II) was observed in 39% of genoid-BMT and 41% of MUD (p=0.83). After statistical adjustment for patient, disease and transplant related characteristics, there was a trend of higher TRM (p=0.08) and a lower incidence of relapse in MUD (p=0.05) compared to genoid-BMT. Therefore LFS was similar between the two groups (p=0.82). Estimated 2 y LFS non adjusted for patients with ALL Phi+ transplanted in CR2 or more was 8+/-5% for genoid-BMT (n=31) compared to 30+/-8% for MUD (n=34). In conclusion relapse incidence is decreased after MUD compared to genoid-BMT probably due to a stronger GvL effect after unrelated transplants. LFS is similar between the two types of transplants, however it is apparently better for patients with ALL ph+ transplanted in CR2 or more. Thus the indications for a MUD in adults with ALL should be the same as the indications for a genoid-BMT and not only indicated in advanced phase of the disease.
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Allogeneic stem cell transplantation after chemotherapy and dose reduced-intensity conditioning for high-risk AML and MDS M. Schleuning, C. Schmid, G. Ledderose, J. Tischer, M. Weisser, M. Humann, H.-J. Kolb (Munich, D) Unfavorable cytogenetic, refractory or relapsed disease and an antecedent hematological disorder define high risk A ML and MDS. Even after conventional allogeneic stem cell transplantation (alloSCT) the outcome is poor. We combined a cytoreductive chemotherapy with alloSCT after dose reduced conditioning. Chemotherapy consisted of Fludarabin (4x30 mg/m²), AraC (4xg/m²) und Amsacrine (4x100 mg/m²). After 3 days of rest, the patients received 4Gy TBI followed by Cyclophosphamide (2x40 resp. 2x60 mg/kg) and ATG (3x10 resp. 3x20 mg/kg, higher doses used with unrelated donors). In the absence of GvHD, the Graft-versus-Leukemia effect was augmented by prophylactic transfusions of donor lymphocytes (DLT) starting day 90 after transplant. 72 patients were treated (CR1 + unfavorable karyotype, delayed response to induction therapy or secondary AML: n=9, CR2: n=7, 1st or 2nd relapse: n=27, refractory: n=23, untreated progressive MDS or secondary AML: n=6). 4 relapsed patients had received an autologous transplant before, and 22 patients had an unfavorable karyotype. Median age was 50.2 (18.5 -65.8) years. 35 patients had a family and 37 an unrelated donor. All patients surviving more than 30 days engrafted, and all but four patients were free of blasts in blood and bone marrow at day 30. Additionally, one patient achieved a CR after discontinuation of immunosuppression. >95% donor chimerism was achieved in 85% of the patients at day 45 and in 92% at day 90. Overall survival and disease free survival was 50% resp. 47% after one and 42% resp. 40% after two years. Interestingly, survival was identical in patients with and without an unfavorable karyotype. TRM was 18% before day 100. 58% of the patients developed acute and 40% developed chronic GvHD. 8 patients relapsed at a median of 102 days from transplant. Discontinuation of immunosuppression and adoptive immunotherapy re-induced remissions in four cases. So far, 12 patients have received prophylactic DLT. Mixed chimerism was converted into complete chimerism in one patient, and 3 patients developed chronic GvHD. To date, none of the 12 patients has relapsed. We conclude that the combination of cytoreductive chemotherapy and intensity reduced conditioning is an attractive approach to the treatment of elderly patients with high risk AML and MDS. Long term remissions can be induced. Prophylactic DLT after transplant is feasible, but further evaluation is necessary to assess its efficacy in maintenance therapy. Myelodysplastic syndrome (MDS) is a clonal haemopoietic stem cell malignancy for which, the only curative therapy is allogeneic haemopoietic stem cell transplantation. This study analysed 210 consecutive allogeneic transplants for MDS and sAML performed in 18 Australasian centres between 1992 and 2000. The subjects were selected from the ABMTRR, which collects registrations of all haemopoietic stem cell transplants performed in Australia and New Zealand. The median age of recipients was 41 years (range 0-61 years) with 181 (86%) being aged >15 years. 116 (55%) of recipients were male and 127 (61%) received a graft from a fully HLA-matched sibling. BM was the stem cell source for 139 pts (64%), PBSC for 66 pts (31%) and cord blood for 2 pts (1%). The use of PBSC (P<0.0005), second transplant (P=0.05) and CD34 dose (p=0.02) were significantly associated with more rapid neutrophil engraftment. Only recipient age was independently associated with more rapid platelet engraftment. The entire group had a 5-year overall survival probability of 32% and a 5-year DFS probability of 31%. TRM to d+100 was 26.2%. Relapse occurred in 52 pts, giving a probability of relapse at 2 yrs of 40%. Overall survival probability was superior for patients transplanted for MDS compared with sAML (37% vs 16%, P=0.03) and for primary MDS c/f therapy-related MDS (35% vs 10%, P<0.0005). On multivariate analysis a shorter time interval from diagnosis to transplantation (P=0.003), a low IPSS score at transplantation (P=0.03), matched sibling transplantation (P<0.0005), younger age (p=0.01) and the use of BM as opposed to PBSC (P<0.0005) were associated with improved survival. 80 (38%) had previously received intensive combination chemotherapy, with no significant difference in overall survival probability (P=0.4), TRM (P=0.4), or relapse (p=0.8). Patients who experienced grades I -II aGVHD had the best 5 -year overall survival probability (41%, compared with 32% for those with no aGVHD and 10% for those with grades III-IV aGVHD, p<0.0005) strongly suggests the presence of a 'graft-versusmyelodysplasia' effect. This study highlights the curative potential of allogeneic transplantation for MDS. Patient transplanted with BM had superior survival to those given PBSC. Until a randomised, controlled clinical trial, BM should be the stem cell source of choice in the transplantation of MDS. The routine use of intensive combination chemotherapy prior to transplantation does not appear beneficial.
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Autologous peripheral stem cell transplantation of patients with high-risk MDS or AML following MDS results in equivalent outcome when compared to autologous bone marrow transplantation T. de Witte, R. Brand, A. van Biezen, J. Cahn, J. Laporte, W. Arcese, B. Bandini, M. Michallet, J. Sierra, A. Goldstone, M. Delforge, N. Kröger, D 
. Niederwieser on behalf of the MDS subcommittee CLWP
Intensive chemotherapy followed by ASCT is a curative treatment option for patients with MDS or AML following MDS (AML-MDS) lacking a donor. Autologous bone marrow transplantation (ABMT) for this indication is associated with prolonged marrow hypoplasia. Therefore, autologous peripheral stem cell transplantation (APSCT) has gradually replaced ABMT as the preferred form of ASCT since 1992. Earlier analyses indicated an increased relapse risk after APSCT, mainly in patients older than 40 years. For this reason we collected additional information of potential prognostic variables, such as transplant year, interval between diagnosis and CR-1, interval between CR-1 and transplant, age, type of MDS (therapy-related vs primary MDS or AML-MDS, and cytogenetics. We analysed the data of 432 patients transplanted in CR-1. The results of ABMT were worse when the transplant was performed before 1993 (22% and 28% 3-year survival resp). For these reasons the final analysis was restricted to 336 patients transplanted after 1992 with either BM (104) or PB (232) 30 (p=0.67) . Also the relapse risk after both forms of ASCT was identical with HR of 1.1. No interaction between age and the source of stem cells could be detected hence the data do not support an age-dependent effect of the source of stem cells. The effect of calendar year was adverse: the HR is around 1.1 (95% C.I. 1.0-1.2; p=0.04) denoting an increase in event rate of 10% per calendar year. However, the mean follow-up time (among patients still alive) is steeply decreasing from 1995 onwards, more than to be expected. This may indicate a selection bias due to mortality overreporting of recently transplanted patients. In conclusion: APSCT results in equivalent outcome compared to ABMT. APSCT is the preferred form of ASCT in view of the more rapid haematopoietic recovery.
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Radio-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk chronic myeloid leukemia or Philadelphia chromosome positive ALL: results of a phase I-II study T. Zenz, I. Buchmann, D. Dohr, R. Schlenk, W. Grimminger, S. von Harsdorf, H. Dohner, S. Reske, D. Bunjes (Ulm, D) Introduction: Patients with Philadelphia chromosome positive ALL and advanced CML have a high risk of relapse even after allogeneic stem cell transplantation (SCT). In order to reduce the relapse rate we chose to intensify the conditioning regimen by adding radioimmunotherapy with labeled anti-CD66 antibody to the conditioning regimen for patients with advanced CML (beyond 1.cP) and highest risk ALL (Philadelphia chromosome positive). Here we report on 18 patients with a minimum follow up of 100 days treated between June 1998 and July 2002. Methods: Prospective study of radio-labeled anti-CD66 -antibody containing conditioning regimen for allogeneic SCT. Results: Over a 4 years period (June 1998 -July 2002) 18 patients (median age 45) with advanced CML (11) and highest risk ALL (7) underwent allogeneic peripheral blood stem cell transplantation after a conditioning regimen including radiolabeled anti-CD66 antibody (Rhenium 188 (17) and Yttrium90 (1)). Of the patients with CML, 5 were in accelerated phase, 5 in 2. cP and 1 in 3.cP. Most patients with ALL were in 1. CR (5) (PR: n=1, 2.CR n=1). Stem cell source included matched related donors (6) matched unrelated donors (8), and haploidentical family donor (4). In addition to the radioimmunotherapy patients received Cyclophosphamide (120mg /kg)(18) and TBI (12Gy)(15) or Busulfan (13,2mg/kg)(3). Patients with haploidentical donors received additional Thiotepa (10mg/kg)(4). The median radiation dose delivered to the marrow by radioimmunotherapy was 13,85 Gy (5,2-21,9). All patients received peripheral blood stem cells which were T-cell depleted by CD34 selection (14) or Campath 1H treatment (4). All but one patient engrafted with a median time to platelet (>25000) and leukocyte (>1000) recovery of 13,5 and 11 days. Acute graft versus host disease (GvHD) developed in 7 out of 18 patients and no grade 3-4 GvHD was seen. TRM was 0% at day 30 and 100. Overall survival is 31% with a median follow-up of 402 days (101-1195) (ALL 54%, CML 36%). Conclusion: Radio-labeled anti-CD66 antibody containing conditioning regimen can deliver significant additional radiation to the bone marrow of patients with advanced CML and highest risk ALL without increasing the early toxicity or TRM. In order to evaluate the benefit of the increased dose intensity on the overall outcome more patients treated with this regimen and longer follow up are needed.
O259 Autologous stem cell transplantation for treatment-related MDS/AML N. Kröger, R. Brand, A. van Biezen, D. Niederwieser, A. Zander, T. de Witte on behalf of the Subcommittee MDS of the Chronic Leukaemia Working Party
Therapy related MDS/AML has a particularly poor prognosis with an estimated one year survival of only 10 to 15% with supportive care alone. We report the results of 65 patients with treatment related MDS/AML who were transplanted from an autograft and reported to the EBMT. The median age was 39 years (range 3-69) and stem cell source was bone marrow (n=31) or peripheral blood progenitor cells (n=30), or the combination of both (n=4). The primary disease were solid tumors (n=37), Hodgkin's Disease (n=13), Non-Hodgkin Lymphoma (n=10), Acute Lymphoblastic Leukemia (n=2) or Myeloproliferative Syndroms (n=3).The type of MDS were as follows: RAEB: n=1 (2%), RAEBt: n=3 (5%) or AML: n=56 (87%). The median time between diagnosis and transplant was 5 months (range 3 -86). The estimated probability of overall and disease free survival at 5 years were 35% (95% CI: 21-49%) and 32% (95%CI: 18-45%), respectively. The probability of relapse was 58% (95%CI: 44-72%) and of treatment related mortality 22% (95%CI: 6-38%). In a univariate analysis for stem cell source, age, disease-type (MDS vs AML), interval between diagnosis and transplant, cytogenetic risk level, conditioning (TBI vs noTBI) and disease status (CR1 vs no CR1), the only significant factor for overall survival at 3 years was age (<40 vs. >40: 47% vs. 19%; p=0.01) and use of TBI (53% vs 33%; p=0.04). Lower relapse rate was seen in patients transplanted in first complete remission (CR1 vs. non-CR1: 48 vs. 89%; p = 0.05). Furthermore, age beyond 40 years resulted in a higher treatment related mortality (47 vs. 7%; p=0.01). In a multivariate analysis, transplantation in first complete remission [HR 0.4 (CI 95%: 0.16-0.9%), p=0.04] and age [HR 1.036 (CI 95%: 1.009-1.064), p=0.08] influenced overall survival significantly. However age and disease status did interact significantly: Among 20 years old not being in CR1 has no effect on OS (HR: 0.9), while among 60 years not being in CR1 a significant effect on OS was seen (HR 0.1) Autologous transplantation may cure a substantial number of patients with treatment r elated MDS/AML especially if they are in first complete remission and of younger age.
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Outcome of unrelated hematopoietic stem cell transplantation for acute myeloid leukemia with or W/O antithymocyte globulin (Atg) for the prophylaxis of GVHD are comparable: two centers analysis N. Basara, A. Yaman, L. Kraut, H. Baurmann, A.A. Fauser, R. Schwerdtfeger (Idar-Oberstein, Wiesbaden, D) Transplantation of hematopoietic stem cells (HSCT) from unrelated donor is increasingly used for the treatment of acute myeloid leukemia (MUD-AML). AML patients (pts) lacking a suitable sibling donor have a probability of approx. 80% to find an HLA-compatible unrelated donor. Between 1994 and 2002, 132 pts with AML received an unrelated HSCT in our two centers. We analysed the outcome, i.e. disease-free survival (DFS) in this group of pts. In addition, the outcome of pts was compared with regard to the use of ATG in the prophylaxis of GvHD, conditioning regimen and disease status at transplant. Both groups were matched with regard to age, FAB classification, stage of the disease and HLA-compatibility of the donor. Median age of pts was 39 (range 16 to 60).The male to female ratio was 70/62. Conditioning for HSCT consisted either of a busulfan (Bu)-in 72 pts or total body irradiation (TBI)-based regimen in 60 pts. The prophylaxis of graft-versus-host disease (GVHD) was CsA/MTX/pred-based for the pts from IdarOberstein (n=68) or CsA/MTX/ATG-based for the pts from Wiesbaden (n=64). Seventy three % of pts have received an HLA-A, -B, and -DRB1 loci matched transplants. Median and average post-transplant follow-up was 8 months with the longest overall survival being 6 years. Estimated 3 y DFS in the AML pts at 5 years was 49% for pts transplanted in first complete remission (CR) (n=65), 18% in relapse (rel) (n=41) and 29% for primary induction failure (PIF) (n=17). There was no difference in the DFS with regard to ATG vs no ATG for the prophylaxis of GvHD. Therefore DFS was similar between the two groups (p=0.21). In addition, there was no difference in the OS regarding the Bu-and TBI-based conditioning regimens (p=0.73).
In conclusion, the results of this retrospective analysis confirm that MUD HSCT is an important treatment option for patients with high-risk AML. Moreover OS is similar between the MUD-AML given ATG compared no ATG for the prophylaxis of GvHD. In order to substantiate our data, a prospective, randomised clinical trial is needed to assess the impact of ATG in the prophylaxis of GvHD in MUD-AML transplants.
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Acute megakaryoblastic leukemia: survival after intensive treatment with autologous or HLA-identical allogeneic transplant L. Garderet, M. Labopin, E. Polge, N.C. Gorin, F 
. Frassoni on behalf of the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation
Aim: Acute megakaryoblastic leukaemia (AML7) patients have a very low survival with standard chemotherapy. We evaluated the outcome after autologous and HLA-identical allogeneic transplantation. We separately analysed children and adults and focused our study on patients in CR1 at transplant. Methods: Between 1986 and 2001, as reported to the EBMT registry, 103 patients underwent an autologous transplantation and 108 an HLA-identical allogeneic transplantation. Patient characteristics: In the autologous group: median age was 1.9 year for children (n=45) and 47 years for adults (n=48). Status at transplant was CR1 in 80% of children and 79% of adults. Source of stem cells was bone marrow (BM) in 78% and peripheral blood (PB) in 22% of cases in children and 42% versus 58% in adults. Chemotherapy without TBI was the conditioning regimen in 97% of children and 74% of adult patients. In the allogeneic group, median age was: 2.8 years (children) and 39 years (adults), status at transplant was CR1 in 57% (children) and 49% (adults), BM was the source of stem cells in 93% (children) and 67% (adults) and TBI was not part of the regimen in 72% of children and 46% of adults. Results: In the autologous transplantation group: the 2-years probabilities (patients in CR1, children and adults) for TRM were respectively 6% and 9%, RI: 42% and 55%, LFS: 52% and 36% and OS: 59% and 38%. In the multivariate analysis, adults had a lower RI if the median age was lower than 45 years (p=0.04, RR=0.41) and if they did not receive TBI (p=0.03, RR=0.37). In the HLA-identical allogeneic transplant group: TRM were respectively 0% and 25%, RI: 33% and 26%, LFS: 67% and 49% and OS: 80% and 42% (children and adults). In the multivariate analysis, patients in CR1 had a lower RI (p=0.003, RR=0.32) with a higher LFS (p<0.0001, RR=0.26) and TRM was higher in adults (p=0.03, RR=13.6). Conclusion: These preliminary data suggest a higher survival after both autologous and HLA-identical allogeneic transplantation compared to known results with chemotherapy alone. For allogeneic transplant, survival was better in patients transplanted in CR1.
Oral Session: Infections (bacterial and fungal)
O262
Itraconazole prevents invasive fungal infection in neutropenic patients: evidence from a meta-analysis of 2,711 patients A. Glasmacher, A. Prentice, M. Gorschlueter, S. Engelhart, C. Hahn, B. Djulbegovic, I. Schmidt-Wolf (Bonn, D; Plymouth, UK; Tampa, USA) Background: Treatment of haematological malignancy with chemotherapy and stem cell transplantation is potentially curative but complicated by invasive fungal infection (invasive fungal infections) with a high mortality rate. Efficacy of prophylaxis against the range of fungi responsible has not yet been proven in numerous trials and meta-analyses but the flaws in these studies as well as new evidence justify this metaanalysis of the trials using itraconazole alone. Methods: Randomized, controlled studies with itraconazole for antifungal prophylaxis in neutropenic patients were identified. The primary endpoint was the incidence of proven invasive fungal infections (localised sino-nasal infections excluded). Findings: Ten studies with 2711 patients/episodes were included. Itraconazole reduced the incidence of proven invasive fungal infection (reduction 44%, P=0.002), the incidence of invasive yeast infections (59%, P=0.003) and the mortality from invasive fungal infections (44%, P=0.02) significantly. The incidence of invasive Aspergillus infections was only reduced in trials using the itraconazole cyclodextrine solution (57%, P=0.03) and not itraconazole capsules (P=0.2; test for heterogeneity between subtotals: P=0.02). The overall mortality was not changed. Adverse effects were rare, hypokalaemia was noted in two trials and higher rate of drug discontinuation was found in trials that compared itraconazole cyclodextrine solution to a control without cyclodextrine. The effect of prophylaxis was clearly associated with a higher bioavailable dose of itraconazole. Interpretation: Antifungal prophylaxis with itraconazole effectively prevents proven invasive fungal infections and reduces mortality from these infections in neutropenic patients with haematological malignancies. The higher doses of the oral cyclodextrine solution of itraconazole are responsible for these benefits.
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The antifungal effectiveness and tolerability of amphotericin B formulations: a systematic review and meta-analysis D.I. Marks, J.P. Barrett, K.A. Vardulaki, C. Conlon, J. Cooke, P. Daza-Ramirez, E.G.V. Evens, P.M. Hawkey, R. Herbrecht, J.M. Moraleda, G.R. Park, S.J. Senn, C 
. Viscoli on behalf of the Amphotericin B Systematic Review Study Group
A systematic literature review was conducted to compare the effectiveness and tolerability between lipid-based formulations of amphotericin B (AmB) and conventional AmB, in treating systemic fungal infections. Databases of published studies (MEDLINE, EMBASE, Biological Abstracts, AIDSLINE, CANCERLIT, CRD database, Cochrane Controlled Trials Register) and unpublished studies (conference abstracts) were interrogated. Outcome measures reviewed were: efficacy, mortality, and adverse reactions. Seven studies (eight publications) fulfilled the predetermined entry criteria. Metaanalysis showed that lipid-based formulations significantly reduced all-cause mortality risk by an estimated 28% compared with conventional AmB (OR: 0.72; CI: 0.54-0.97), although no significant difference in efficacy was found (OR: 1.21; CI: 0.98-1.49). Comparing the lipid-based formulations, Abelcet(R) and Ambisome(R), with conventional AmB, the number-needed-totreat (NNT) to prevent one death was 31; and the risk of serum creatinine doubling was significantly reduced by an estimated 58% (OR: 0.42; CI: 0.33-0.54) with an NNT of six. There was no significant risk reduction in infusion-related reactions with lipidbased formulations. This study demonstrated advantages with lipid-based formulations over conventional AmB in terms of reduced risk of mortality and renal toxicity.
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Influence of cell dose on the response to granulocyte transfusions in neutropenic patients with severe infections C. Peters, M. Minkov, S. Matthes-Martin, U. Pötschger, V. Witt, G. Mann, P. Höcker, N. Worel, J. Stary, T. Klingebiel, H. Gadner, H. Einsele (Vienna, A; Prague, CZ; Frankfurt, Tuebingen, D) Severe infections in neutropenic immunocompromised patients are still associated with high mortality despite of appropriate antibacterial and antifungal treatment. In a prospective study we evaluated the feasibility and efficacy of granulocyte transfusions (GT) in paediatric and adult patients with malignancies or haematological disorders. Indication for GT were severe bacterial or fungal infections. A total of 94 septic episodes (32 bacterial, 50 fungal, 12 unknown) in 78 patients are included in the present analysis. A total of 785 GTs (371 from prednisolone-primed volunteers and 414 from rhG-CSF-stimulated family donors) were administered. All GT were irradiated with 30 Gy and infused as soon as possible after harvesting. We evaluated the response to GT in the paediatric population (age <18years, 43 patients) compared to that in adult patients (age >18 years 35 patients). The median number of GT per septic episode was 8.5 (2-40) in the paediatric and 4 (1-65) in the adult group, respectively. Children received a median of 0.44 G ANC/kg body weight with prednisolone-elicited GT and 2.29 G ANC/kg with G-CSF elicited GT. In contrast, adults received 0.29 G ANC/kg (prednisolonelicited GT) or 0,46 G ANC/kg (G-CSF elicited GT), respectively. Paediatric patients receiving prednisolone-elicited GT achieved a median ANC increment of 0.30 G/l (range: -1.87 to +3.71) after the first LT versus 1.48 G/l (range: 0 to +18.61) in patients receiving rhG-CSF elicited GT. In contrast, no signifant difference was found in the cohort of adult pts. The probability to reach sustained ANC >0.5 G/l within 7 days of GT was 77±5% in the paediatric group versus 39±5% in the group of adult patients. Correlated to patient's body weight this variable was 90±5% for weight <30 kg, 68±8% for weight 30-60 kg, 31±4% for weight >60 kg. No significant influence was found by the time of neutropenia before GT, the underlying disease and the indication
